クラモチ　ヒデカズ   KURAMOCHI HIDEKAZU   倉持　英和    所属   医学部 医学科（東京女子医科大学病院）    職種   准教授
論文種別	原著
言語種別	英語
査読の有無	査読あり
表題	Amphiregulin/epiregulin mRNA Expression and Primary Tumor Location in Colorectal Cancer.
掲載誌名	正式名：Anticancer research 略　 称：Anticancer Res ISSNコード：17917530/02507005
巻・号・頁	39(9),pp.4729-4736
著者・共著者	KURAMOCHI Hidekazu, NAKAJIMA Go, HAYASHI Kazuhiko, ARAIDA Tatsuo, YAMAMOTO Masakazu
担当区分	筆頭著者,責任著者
発行年月	2019/09
概要	BACKGROUND/AIM:Amphiregulin (AREG) and epiregulin (EREG) mRNA expression levels are predictors of response to anti-EGFR antibody therapy. Left-sided colon cancer is more sensitive to anti-EGFR antibodies than right-sided, although the mechanism is unclear. The aim of this study was to determine the relationship between AREG, EREG mRNA expression levels and tumor location as well as the efficacy of anti-EGFR antibody agents.MATERIALS AND METHODS:Real-time PCR was used to assess AREG and EREG mRNA expression in metastatic colorectal cancer (CRC) samples from 153 patients.RESULTS:Among KRASwt samples, high AREG expression (AREGHigh) was significantly more common in left-sided tumors than in right-sided. Among patients who received anti-EGFR antibody, response rates were significantly higher in AREGHigh than in AREGLow In the left-sided tumor group, overall survival was significantly longer in patients with high EREG levels than with low levels, whereas the right-sided tumor group showed no survival difference between them.CONCLUSION:AREG and EREG mRNA expression levels in left-sided CRC were higher than in right-sided tumors. This may help explain why left-sided CRC is more responsive to anti-EGFR antibodies.
DOI	10.21873/anticanres.13655
PMID	31519572